Striving for new therapies that make patients' lives better

We have an extensive pipeline of investigational product candidates that are progressing through all stages of human clinical trials. Our product candidates address many serious medical conditions including cancer, eye diseases, inflammatory diseases, pain, cardiovascular diseases, and allergic conditions.

Peter Powchik, M.D. Senior Vice President, Clinical Development "We have the enviable ability to add several additional fully human antibodies to the clinical pipeline each year due to the productivity of our discovery and development platforms."

Looking for Information on Investigator Initiated Studies?
http://iisgrants.regeneron.com

VelociGene® Technology

Regeneron scientists have developed novel methods for assigning functions to genes and creating preclinical disease models.

More On Our Technology Platform

Product Candidate

Category Under Study

Alirocumab (REGN727)
PCSK9 Antibody
LDL cholesterol reduction

Sarilumab (REGN88)
IL-6R Antibody

Rheumatoid arthritis
Dupilumab (REGN668)
IL-4R Antibody
Atopic dermatitis
Dupilumab (REGN668)
IL-4R Antibody
Asthma
Chronic sinusitis with nasal polyposis

Sarilumab (REGN88)
IL-6R Antibody

Non-infectious Uveitis
REGN1033
GDF8 Antibody
Skeletal muscle disorders
Fasinumab (REGN475)*
NGF Antibody
*On partial clinical hold
Enoticumab (REGN421)
DII4 Antibody
Advanced malignancies

Nesvacumab (REGN910)
Ang2 Antibody

Advanced malignancies
REGN910-3
Ang2 Antibody + Aflibercept
Ophthalmology
REGN2176-3
PDGFR-beta Antibody + Aflibercept
Ophthalmology
REGN1400
ERBB3 Antibody
Advanced malignancies
REGN1979
CD20/CD3 Antibody
Advanced malignancies
REGN2222
Respiratory Syncytial Virus (RSV) Antibody
Infectious disease
REGN1908-1909 Allergic disease
REGN1500
Angptl-3 Antibody
Lipid disorders
REGN1154 Undisclosed
REGN1193 Undisclosed

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Close
Form content here please :)